"Hela人宮頸癌細(xì)胞全年復(fù)蘇|已有STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長(zhǎng)特性：貼壁生長(zhǎng)

【細(xì)胞培養(yǎng)經(jīng)驗(yàn)分享】啟蒙老師的重要性：一般進(jìn)實(shí)驗(yàn)室都有師兄師姐帶著做，他們就是你做細(xì)胞的啟蒙老師。他們的操作手法、細(xì)節(jié)、理論講解就成了你操作的準(zhǔn)則，如營(yíng)養(yǎng)液、細(xì)胞瓶的擺放位置、滅菌處理程序、開蓋手法、細(xì)胞吹打手法等等。要學(xué)會(huì)他們的正確操作，在第一次的時(shí)候就要重視。像養(yǎng)孩子一樣養(yǎng)細(xì)胞，細(xì)胞有時(shí)真的很脆弱，最好每天都去看看它，以防止出現(xiàn)培養(yǎng)箱缺水、缺二氧化碳、停電、溫度不夠等異常現(xiàn)象，也好及時(shí)解決這些意外，避免重復(fù)實(shí)驗(yàn)帶來(lái)的更大痛苦。好細(xì)胞要及時(shí)保種：細(xì)胞要分批傳代，這樣即使有一批出了問題，還有一批備用的。像后者一般人可能不容易做到。但這是我血的教訓(xùn)，有一次細(xì)胞污染了，全軍覆沒。當(dāng)時(shí)可后悔沒有保種。細(xì)胞跟人一樣，不同的細(xì)胞，培養(yǎng)特性是不一樣的。培養(yǎng)過程中要細(xì)細(xì)體會(huì)，不同細(xì)胞系使用不同的培養(yǎng)基和血清。

換液周期：每周2-3次

T1-73 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：PM6細(xì)胞、C12細(xì)胞、CL MC/9細(xì)胞

PG-LH7 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：RSMC細(xì)胞、T/GHA-VSMC細(xì)胞、CAL 78細(xì)胞

Virginia Mason Research Center-Lung Cancer D Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：H211細(xì)胞、CLL-CII細(xì)胞、bEnd.3[BEND3]細(xì)胞

背景信息：HeLa是第一個(gè)來(lái)自人體組織經(jīng)連續(xù)培養(yǎng)獲得的非整倍體上皮樣細(xì)胞系，它由GeyGO等在１９５１年從３１歲女性黑人的宮頸癌組織建立。經(jīng)原始組織切片重新觀察，Jones等將其診斷為腺癌。已知該細(xì)胞系含有人乳頭狀瘤病毒HPV１８序列，需在２級(jí)生物安全防護(hù)臺(tái)操作。該細(xì)胞角蛋白陽(yáng)性，p５３表達(dá)量較低，但表達(dá)正常水平的pRB（視網(wǎng)膜母細(xì)胞瘤抑制因子）。

Hela人宮頸癌細(xì)胞全年復(fù)蘇|已有STR圖譜

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

DSMZ菌株保藏中心成立于1969年，是德國(guó)的國(guó)家菌種保藏中心。該中心一直致力于細(xì)菌、真菌、質(zhì)粒、抗菌素、人體和動(dòng)物細(xì)胞、植物病毒等的分類、鑒定和保藏工作。DSMZ菌種保藏中心是歐洲規(guī)模最大的生物資源中心，保藏有動(dòng)物細(xì)胞500多株。Riken BRC成立于1920年，是英國(guó)的國(guó)家菌種保藏中心。該中心一直致力于細(xì)菌、真菌、植物病毒等的分類、鑒定和保藏工作。日本Riken BRC(Riken生物資源保藏中心)是全球三大典型培養(yǎng)物收集中心之一。Riken保藏中心提供了很多細(xì)胞系。在世界范圍內(nèi)，這些細(xì)胞系，都在醫(yī)學(xué)、科學(xué)和獸醫(yī)中具有重要意義。Riken生物資源中心支持了各種學(xué)術(shù)、健康、食品和獸醫(yī)機(jī)構(gòu)的研究工作，并在世界各地不同組織的微生物實(shí)驗(yàn)室和研究機(jī)構(gòu)中使用。

SCI1 Cells;背景說(shuō)明：胚胎；自發(fā)永生;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：HC11 Mammary Epithelium細(xì)胞、SK-NSH細(xì)胞、PIGI細(xì)胞

LM-TK- Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：RPTC細(xì)胞、ID8細(xì)胞、GC-2spd(ts)細(xì)胞

CoCL3 Cells;背景說(shuō)明：DLD-１是１９７７-１９７９年間D.L.Dexter和同事分離的兩株結(jié)直腸腺癌細(xì)胞株中的一株。在ATCC和其它地方進(jìn)行的DNAfingerprinting和染色體組型分析表明這株細(xì)胞與HCT-１５(CCL-２２５)相似，說(shuō)明這兩者是來(lái)自同一個(gè)人的不同克隆。他們的遺傳起源可通過DNAfingerprinting證實(shí)，但染色體組型分析顯示它們?nèi)狈θ旧w標(biāo)記一致改變或數(shù)目上一致改變。細(xì)胞的CSAp陰性(CSAp-)。DLD-１細(xì)胞的p５３抗原表達(dá)呈陽(yáng)性(p５３抗原產(chǎn)生了一個(gè)C->;傳代方法：消化５分鐘。１：２。４-５天長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：H1355細(xì)胞、H2228細(xì)胞、T-ALL1細(xì)胞

4e2 Cells(提供STR鑒定圖譜)

來(lái)源說(shuō)明：細(xì)胞主要來(lái)源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫(kù)

物種來(lái)源：人源、鼠源等其它物種來(lái)源

Hela人宮頸癌細(xì)胞全年復(fù)蘇|已有STR圖譜

形態(tài)特性：上皮細(xì)胞樣

貼壁細(xì)胞消化傳代時(shí)通常采用兩種方法：一、加入胰酶等細(xì)胞脫落后，再加培養(yǎng)基中止胰酶作用，離心傳代；二、加入胰酶后，鏡下觀察待細(xì)胞始脫落時(shí)，棄胰酶，加培養(yǎng)分瓶。但前者太麻煩，而后者有可能對(duì)細(xì)胞施加胰酶選擇，因?yàn)榭偸琴N壁不牢的細(xì)胞先脫落，對(duì)腫瘤細(xì)胞來(lái)說(shuō)，這部分細(xì)胞有可能是惡性程度較GAO的細(xì)胞亞群。一種簡(jiǎn)單的消化傳代方法。加入PBS洗去血清或加入胰酶先中和血清的作用(３０s)，棄之，再加入適量胰酶作用１０s-４０s(根據(jù)細(xì)胞消化的難易程度)，棄之，這樣依賴殘余的胰酶就可將細(xì)胞消化單細(xì)胞。對(duì)于較難消化的細(xì)胞，可以用２%利多卡因消化５-８分鐘，然后再棄去，加培養(yǎng)基吹打也可以，對(duì)細(xì)胞的影響不大。不用PBS也不用Hanks洗，只要把舊培養(yǎng)吸的干凈一點(diǎn)，直接加酶消化應(yīng)該不會(huì)有什么問題。棄培養(yǎng)后，用０.０４%的EDA沖洗一次，再用１/４v的０.０４%的EDA室溫孵育５min，棄取大部分EDA，加入與剩余EDA等量的胰酶(預(yù)熱)總體積１/１０v。消化到有細(xì)胞脫落。不過有人說(shuō)EDA對(duì)細(xì)胞不HAO，有證據(jù)嗎？培養(yǎng)的BASMC：倒掉舊培養(yǎng)加入少量胰酶沖一下，倒掉再加入０.１２５-０.２５%胰酶約６-１０滴或１ml(２５ml bole)消化再加入適量新培養(yǎng)基中和，并分瓶這種方法簡(jiǎn)單、省事；效果很HAO并且不損失細(xì)胞！

LM3 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HCC1500細(xì)胞、UCLA-SO-M14細(xì)胞、H-35細(xì)胞

WPMY-1 Cells;背景說(shuō)明：肌成纖維基質(zhì)細(xì)胞株,WPMY-１,與RWPE-１cells(ATCCCRL-１１６０９)一樣，來(lái)源于同一張成人前列腺組織切片的周圍區(qū)域的基質(zhì)細(xì)胞。通過一個(gè)pRSTV質(zhì)料結(jié)構(gòu)，用SV４０大T抗原對(duì)基質(zhì)細(xì)胞進(jìn)行永生化。WPMY-１細(xì)胞，與RWPE-１細(xì)胞及其它上皮細(xì)胞衍生株一樣，屬于來(lái)源于同一個(gè)前列腺的一系列細(xì)胞株。由于它們來(lái)源于同一個(gè)前列腺的周圍區(qū)域，WPMY-１細(xì)胞株對(duì)于研究分泌和基質(zhì)與上皮細(xì)胞相互作用尤其有用。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成肌細(xì)胞;相關(guān)產(chǎn)品有：8226細(xì)胞、K7M2-WT細(xì)胞、VM Cub 1細(xì)胞

BEAS2B Cells;背景說(shuō)明：從一位非癌個(gè)體的正常人支氣管上皮病理切片分離出上皮細(xì)胞。這些細(xì)胞用腺病毒１２-SV４０病毒雜交病毒感染并克隆。DEAS-２B細(xì)胞保留了對(duì)血清反應(yīng)進(jìn)行鱗關(guān)分化的能力，并有用于篩選誘導(dǎo)或影響分化及致癌的化學(xué)或生物制劑。細(xì)胞角蛋白及SV４０抗原染色陽(yáng)性。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：JOSK-M細(xì)胞、MCA 38細(xì)胞、WM-239-A細(xì)胞

SNU-484 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：T.T細(xì)胞、KTC-1細(xì)胞、EBNA293細(xì)胞

NCI-H3255 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：CATH-a細(xì)胞、C8166-CD4細(xì)胞、H-196細(xì)胞

HCFB（HCF） Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：WEHI-231細(xì)胞、MG63細(xì)胞、OVCAR 420細(xì)胞

HDQP1 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：Tissue Culture-1細(xì)胞、HuP-T4細(xì)胞、Ect1/E6E7細(xì)胞

D-341 Med Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：髓母細(xì)胞樣;相關(guān)產(chǎn)品有：OVCAR8/ADR細(xì)胞、EOC-20細(xì)胞、HuCC-T1細(xì)胞

H740 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：Neuro2a細(xì)胞、SUM-190細(xì)胞、IOSE80細(xì)胞

PK136 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：NFS60細(xì)胞、Vero-76細(xì)胞、Institute for Medical Research-90細(xì)胞

CHP-100 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：PC9細(xì)胞、CAL-33細(xì)胞、HPDE6c7細(xì)胞

IEC-6 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：AdHek細(xì)胞、OCI-LY-7細(xì)胞、Hs 839.T細(xì)胞

SW 403 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：６傳代，每周換液２-３次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：NBL_S細(xì)胞、4T1-LUC細(xì)胞、A375細(xì)胞

MUTZ1 Cells;背景說(shuō)明：骨髓增生異常綜合征；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：P3-X63Ag8細(xì)胞、Human Epithelioma-2細(xì)胞、HITT15細(xì)胞

Tu-177 Cells;背景說(shuō)明：喉鱗癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：MUG-Chor1細(xì)胞、NIH:OVCAR-10細(xì)胞、WM2664細(xì)胞

MLA 144 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：ATDC-5細(xì)胞、CAL 51細(xì)胞、NCI-H1650細(xì)胞

GC-1spg Cells;背景說(shuō)明：精原細(xì)胞；SV４０轉(zhuǎn)化；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：SK.MEL.2細(xì)胞、NCI-H1299細(xì)胞、YES 2細(xì)胞

Abcam HCT 116 RNF2 KO Cells(提供STR鑒定圖譜)

AG08182 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line GST067 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XB130 Cells(提供STR鑒定圖譜)

BMS2 Cells(提供STR鑒定圖譜)

CMM8 Cells(提供STR鑒定圖譜)

DA03635 Cells(提供STR鑒定圖譜)

deltaTCAR-3 Cells(提供STR鑒定圖譜)

GM02587 Cells(提供STR鑒定圖譜)

SK-Col-1 Cells;背景說(shuō)明：該細(xì)胞來(lái)源于結(jié)直腸病人的轉(zhuǎn)移性腹水。;傳代方法：１：２-１：３傳代，每周２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：H-1838細(xì)胞、NIE-115細(xì)胞、TYK-nu細(xì)胞

HO1-N-1 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：143TK-細(xì)胞、NCIH847細(xì)胞、YD15細(xì)胞

KOPN-8 Cells;背景說(shuō)明：B淋巴細(xì)胞白血病；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：NCI-H1954細(xì)胞、FRO 81-2細(xì)胞、SW 1088細(xì)胞

Karpas 299 Cells;背景說(shuō)明：間變性大細(xì)胞淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：HNE-1細(xì)胞、AML-12細(xì)胞、RINm5F細(xì)胞

3 LL Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：UM-UC14細(xì)胞、NCI-H1954細(xì)胞、GM03671細(xì)胞

BT 549 Cells;背景說(shuō)明：該細(xì)胞１９７８年由W.G.Coutinho和E.Y.Lasfargues建系，源自一位７２歲患有乳腺導(dǎo)管癌的白人女性，來(lái)源組織包括乳頭及浸潤(rùn)導(dǎo)管。該細(xì)胞形態(tài)包括上皮樣細(xì)胞及多核巨細(xì)胞，可分泌一種粘性物質(zhì)。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：DU4475細(xì)胞、HS-729細(xì)胞、Mouse podocyte細(xì)胞

NBL-S Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：CZ-1細(xì)胞、H-1395細(xì)胞、U-373MG ATCC細(xì)胞

OUMS-23 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：210RCY3-Ag1.2.3細(xì)胞、SF 763細(xì)胞、COLO206F細(xì)胞

Hela人宮頸癌細(xì)胞全年復(fù)蘇|已有STR圖譜

NP69SV40T Cells;背景說(shuō)明：鼻咽；上皮細(xì)胞；SV４０轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：MC3T3E1細(xì)胞、HOEC細(xì)胞、MGHU1細(xì)胞

TE-85 Cells;背景說(shuō)明：骨肉瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：Calf Pulmonary Artery 47細(xì)胞、MDCK Type II細(xì)胞、COLO-320細(xì)胞

SKMEL-24 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：星形的;相關(guān)產(chǎn)品有：MDA-134細(xì)胞、AE 1201細(xì)胞、MV4II細(xì)胞

NCI H2106 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：IPLB-SF-21細(xì)胞、Human podocyte細(xì)胞、TE671/RD細(xì)胞

PLA 802 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：MCF-7ADR細(xì)胞、Fukuoka University-Malignant mixed Mullerian Tumor-1細(xì)胞、MGH-UI細(xì)胞

TALL-1 [Human adult T-ALL] Cells;背景說(shuō)明：該細(xì)胞源于一名復(fù)發(fā)T-ALL（急性T淋巴細(xì)胞性白血?。┑膬和耐庵苎?；具有很強(qiáng)的細(xì)胞毒性，體內(nèi)體外實(shí)驗(yàn)中都能破壞腫瘤細(xì)胞；IL-２可使細(xì)胞更好地生長(zhǎng)；α/β TCR陽(yáng)性，γ/δ TCR陰性；可產(chǎn)生IFNγ、TNF-α和GM-CSF。;傳代方法：維持細(xì)胞密度在４×１０５-１×１０６ cells/ml之間，２-３天換液１次　;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：NCI-1155細(xì)胞、H-2052細(xì)胞、Panc05.04細(xì)胞

OCI-Ly 7 Cells;背景說(shuō)明：彌漫大B淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：H220細(xì)胞、253J-BV細(xì)胞、Tsup-1細(xì)胞

GM19813 Cells(提供STR鑒定圖譜)

HAP1 IRAK2 (-) 2 Cells(提供STR鑒定圖譜)

PC-14 Cells;背景說(shuō)明：肺腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：SW 982細(xì)胞、DV90細(xì)胞、C33A細(xì)胞

CEM-T4 Cells;背景說(shuō)明：急性T淋巴細(xì)胞白血??；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：MDA-MB 468細(xì)胞、OCI-AML-2細(xì)胞、MDCK (NBL-2)細(xì)胞

Biologics Standards-Cercopithecus-1 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：H-810細(xì)胞、KAT-5細(xì)胞、MB39細(xì)胞

Saos2 Cells;背景說(shuō)明：該細(xì)胞是FoghJ和TrempeG分離和鑒定的眾多人類腫瘤細(xì)胞系中的一種；該細(xì)胞來(lái)自一位１１歲的白人女性的骨肉瘤組織?；颊呓?jīng)過放療以及甲喋呤、阿霉素、長(zhǎng)春新堿、環(huán)磷酰胺和aramycin-C等多種藥物治療。該細(xì)胞在免疫抑制小鼠中不致瘤，細(xì)胞表達(dá)表皮生長(zhǎng)因子EGF受體、轉(zhuǎn)化生長(zhǎng)因子β（１型和２型）受體。;傳代方法：１：２-１：４傳代；每周１-２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣；多角形;相關(guān)產(chǎn)品有：BHK21細(xì)胞、CL MC/9細(xì)胞、RH-30細(xì)胞

HCE Cells;背景說(shuō)明：角膜上皮細(xì)胞；Ad-SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：HEC-1-A細(xì)胞、SMA560細(xì)胞、LUDLU-1細(xì)胞

HPAF-I Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：KM.12細(xì)胞、HC11 Mammary Epithelium細(xì)胞、Hs 832(C).T細(xì)胞

Karpas-422 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：Colon 38細(xì)胞、T.T細(xì)胞、Caco-2/ATCC細(xì)胞

NGP Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：CEM-C1細(xì)胞、K299細(xì)胞、MRC-9細(xì)胞

HPS0846 Cells(提供STR鑒定圖譜)

JNUCK-2 Cells(提供STR鑒定圖譜)

MDCC-HP28 Cells(提供STR鑒定圖譜)

ND41016 Cells(提供STR鑒定圖譜)

PSF [Pelodiscus] Cells(提供STR鑒定圖譜)

Ubigene HeLa UBE3C KO Cells(提供STR鑒定圖譜)

XPH4PV Cells(提供STR鑒定圖譜)

HG01101 Cells(提供STR鑒定圖譜)

TW-039 Cells;背景說(shuō)明：鼻咽癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：RT-4細(xì)胞、102PT細(xì)胞、GalK 1細(xì)胞

Hep-G2/C3A Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：６傳代，每周換液２次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：alpha TC1-6細(xì)胞、BJA-B-1細(xì)胞、aTC1-6細(xì)胞

NK62a Cells;背景說(shuō)明：這株細(xì)胞有EB病毒基因組。;傳代方法：１：２傳代。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：懸浮生長(zhǎng) ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：OV-1063細(xì)胞、ZYM-SVEC01細(xì)胞、PG-LH7細(xì)胞

Cloudman S91 melanoma clone M-3 Cells;背景說(shuō)明：黑色素瘤；雄性；DBA;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：451Lu細(xì)胞、BNL CL.2細(xì)胞、HBL-1 [Human diffuse large B-cell lymphoma]細(xì)胞

SNU-C2B Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：MDA-MB-435細(xì)胞、H-82細(xì)胞、HuLEC-5a細(xì)胞

SNU-C2B Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：MDA-MB-435細(xì)胞、H-82細(xì)胞、HuLEC-5a細(xì)胞

H-35 Cells;背景說(shuō)明：在糖皮質(zhì)激素、胰島素或cAMP衍生物的誘導(dǎo)下可以產(chǎn)生酪酸基轉(zhuǎn)移酶；可被逆轉(zhuǎn)錄病毒感染；可產(chǎn)生白蛋白、轉(zhuǎn)鐵蛋白、凝血酶原；在AxC大鼠中可以成瘤。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：KP 4細(xì)胞、SUDHL2細(xì)胞、BSC1細(xì)胞

H647 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代；每周換液２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：DMS-273細(xì)胞、FRhK4細(xì)胞、Reuber-H-35 hepatoma細(xì)胞

RA Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：T47D細(xì)胞、NCIH2291細(xì)胞、MV522細(xì)胞

Nb2 Cells;背景說(shuō)明：惡性淋巴瘤；雄性；Nb;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：C-4I細(xì)胞、C32-mel細(xì)胞、U-251MG細(xì)胞

SNUC2A Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周兩次換液;生長(zhǎng)特性：松散附著、多單元的聚合;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：A 549細(xì)胞、Panc_02_03細(xì)胞、Michigan Cancer Foundation-12A細(xì)胞

SNU-719 Cells;背景說(shuō)明：胃癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：HcerEpic細(xì)胞、P36細(xì)胞、Sp2/0-Ag14細(xì)胞

SK-GT-4 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：6-10B細(xì)胞、H1963細(xì)胞、M2-10B4細(xì)胞

V 79-4 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：FHs 74 Int細(xì)胞、K 562細(xì)胞、AU-565細(xì)胞

SHSY-5Y Cells;背景說(shuō)明：據(jù)報(bào)道，該細(xì)胞的密度可高達(dá)１×１０６cells/cm２，具有中等水平的多巴胺β羥化酶的活性。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HEL-1細(xì)胞、SKLMS-1細(xì)胞、Human Corneal Epithelial cells-Transformed細(xì)胞

SMS-KCN-A Cells(提供STR鑒定圖譜)

CMT-93 Cells;背景說(shuō)明：結(jié)腸癌；C５７BL/ICRF;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：Bac1 2F5細(xì)胞、D341MD細(xì)胞、H1105細(xì)胞

HLE-B3 Cells;背景說(shuō)明：晶狀體；Ad１２-SV４０轉(zhuǎn)化；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：2PK-3細(xì)胞、HTSMC細(xì)胞、RPE-hTERT細(xì)胞

3T3-A31 Cells;背景說(shuō)明：胚胎；成纖維；自發(fā)永生；雄性；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：RBE細(xì)胞、Sun Yat-sen university Ophtalmic center-Retinoblastoma 50細(xì)胞、SupB15WT細(xì)胞

BV-2 Cells;背景說(shuō)明：源于C５７BL/６小鼠小膠質(zhì)細(xì)胞，表達(dá)核v-myc、染色體v-raf癌基因，表面表達(dá)envgp７０抗原，在形態(tài)學(xué)、表型及功能上有吞噬細(xì)胞的特征。;傳代方法：１：６傳代；２-３天１次。;生長(zhǎng)特性：半貼壁生長(zhǎng);形態(tài)特性：多形型;相關(guān)產(chǎn)品有：SKG IIIa細(xì)胞、INS1-E細(xì)胞、Mo7e細(xì)胞

U-87 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：LLC-WRC 256細(xì)胞、TE-12細(xì)胞、McArdle RH-7777細(xì)胞

EFM-192C Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：C-33A細(xì)胞、MDAPC2B細(xì)胞、293-H細(xì)胞

CMEC/D3 Cells;背景說(shuō)明：腦微血管；內(nèi)皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：DB細(xì)胞、GM00215A細(xì)胞、FBHE細(xì)胞

HNEpC Cells;背景說(shuō)明：鼻粘膜；上皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：Jurkat-77細(xì)胞、M-NFS-60細(xì)胞、C4-I細(xì)胞

Hela人宮頸癌細(xì)胞全年復(fù)蘇|已有STR圖譜

Reuber-H-35 hepatoma Cells;背景說(shuō)明：在糖皮質(zhì)激素、胰島素或cAMP衍生物的誘導(dǎo)下可以產(chǎn)生酪酸基轉(zhuǎn)移酶；可被逆轉(zhuǎn)錄病毒感染；可產(chǎn)生白蛋白、轉(zhuǎn)鐵蛋白、凝血酶原；在AxC大鼠中可以成瘤。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HCC-1588細(xì)胞、MPC5細(xì)胞、SW-527細(xì)胞

SUM190 Cells;背景說(shuō)明：乳腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：SW 780細(xì)胞、L-929細(xì)胞、BALB 3T3 clone A31細(xì)胞

Kit-225-K6 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：OVCA-420細(xì)胞、H1092細(xì)胞、SUDHL-8細(xì)胞

TSU-Pr1 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：H1568細(xì)胞、CMT 93細(xì)胞、HME-1細(xì)胞

H1155 Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：SK UT 1細(xì)胞、MH-22a細(xì)胞、RCC4細(xì)胞

16HBE Cells;背景說(shuō)明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：OCI Ly19細(xì)胞、MOLT 3細(xì)胞、MDA 1386細(xì)胞

BayGenomics ES cell line RRN258 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YHA367 Cells(提供STR鑒定圖譜)

H280-4 Cells(提供STR鑒定圖譜)

PA317 LXSN 16E6E7 Cells(提供STR鑒定圖譜)

AFRC MAC 22 Cells(提供STR鑒定圖譜)

HOS-143B/DOXR8 Cells(提供STR鑒定圖譜)

" "PubMed=13261081

Moore A.E., Sabachewsky L., Toolan H.W.

Culture characteristics of four permanent lines of human cancer cells.

Cancer Res. 15:598-602(1955)

PubMed=16589695; DOI=10.1073/pnas.41.7.432; PMCID=PMC528114

Puck T.T., Marcus P.I.

A rapid method for viable cell titration and clone production with HeLa cells in tissue culture: the use of X-irradiated cells to supply conditioning factors.

Proc. Natl. Acad. Sci. U.S.A. 41:432-437(1955)

PubMed=14031339

Katzberg A.A.

The effect of space flights on living human cells aboard Discoverer XVIII.

Tech. Doc. Rep. SAMTDR USAF Sch. Aerosp. Med. 62:43.1-43.4(1962)

PubMed=14185313; DOI=10.1126/science.146.3641.241

Cell Culture Collection Committee

Animal cell strains. The Cell Culture Collection Committee has assembled and certified 23 strains of animal cells.

Science 146:241-243(1964)

PubMed=5668122; DOI=10.3181/00379727-128-33119

Peterson W.D. Jr., Stulberg C.S., Swanborg N.K., Robinson A.R.

Glucose-6-phosphate dehydrogenase isoenzymes in human cell cultures determined by sucrose-agar gel and cellulose acetate zymograms.

Proc. Soc. Exp. Biol. Med. 128:772-776(1968)

DOI=10.1007/BF02618370

Stulberg C.S., Coriell L.L., Kniazeff A.J., Shannon J.E.

The animal cell culture collection.

In Vitro 5:1-16(1970)

PubMed=4942173; DOI=10.1097/00006250-197112000-00028

Jones H.W. Jr., McKusick V.A., Harper P.S., Wuu K.-D.

George Otto Gey (1899-1970). The HeLa cell and a reappraisal of its origin.

Obstet. Gynecol. 38:945-949(1971)

DOI=10.1007/978-1-4757-1647-4_13

Biedler J.L.

Chromosome abnormalities in human tumor cells in culture.

(In book chapter) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York; USA (1975)

PubMed=1246620; DOI=10.1126/science.1246620

Hsu S.H., Schacter B.Z., Delaney N.L., Miller T.B., McKusick V.A., Kennett R.H., Bodmer J.G., Young D., Bodmer W.F.

Genetic characteristics of the HeLa cell.

Science 191:392-394(1976)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x

Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.

Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.

Tissue Antigens 11:279-286(1978)

PubMed=6256643; DOI=10.1038/288724a0

Day R.S. 3rd, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D.

Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains.

Nature 288:724-727(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239

Wright W.C., Daniels W.P., Fogh J.

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=6358339; DOI=10.1093/jhmas/38.4.415

Brown R.W., Henderson J.H.M.

The mass production and distribution of HeLa cells at Tuskegee Institute, 1953-55.

J. Hist. Med. Allied Sci. 38:415-431(1983)

PubMed=6401685; DOI=10.1007/BF02617989

Halton D.M., Peterson W.D. Jr., Hukku B.

Cell culture quality control by rapid isoenzymatic characterization.

In Vitro 19:16-24(1983)

PubMed=6825208; DOI=10.1093/carcin/4.2.199

Yarosh D.B., Foote R.S., Mitra S., Day R.S. 3rd

Repair of O6-methylguanine in DNA by demethylation is lacking in Mer- human tumor cell strains.

Carcinogenesis 4:199-205(1983)

PubMed=2983228; DOI=10.1038/314111a0

Schwarz E., Freese U.-K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., zur Hausen H.

Structure and transcription of human papillomavirus sequences in cervical carcinoma cells.

Nature 314:111-114(1985)

PubMed=2990217; PMCID=PMC1888002

Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.

Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.

Am. J. Pathol. 119:361-366(1985)

CLPUB00262

Gold M.

A conspiracy of cells. One woman's immortal legacy and the medical scandal it caused.

(In book) ISBN 9780887060991; pp.1-171; State University of New York Press; Albany; USA (1986)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=3028716; DOI=10.1159/000132342

Popescu N.C., DiPaolo J.A., Amsbaugh S.C.

Integration sites of human papillomavirus 18 DNA sequences on HeLa cell chromosomes.

Cytogenet. Cell Genet. 44:58-62(1987)

PubMed=3180844; DOI=10.1159/000132579

Chen T.-R.

Re-evaluation of HeLa, HeLa S3, and HEp-2 karyotypes.

Cytogenet. Cell Genet. 48:19-24(1988)

PubMed=3371749; DOI=10.1016/0090-8258(88)90029-7

Grenman S.E., Shapira A., Carey T.E.

In vitro response of cervical cancer cell lines CaSki, HeLa, and ME-180 to the antiestrogen tamoxifen.

Gynecol. Oncol. 30:228-238(1988)

PubMed=1522048; DOI=10.1007/BF02634140

Kataoka E., Honma M., Ohnishi K., Sofuni T., Mizusawa H.

Application of highly polymorphic DNA markers to the identification of HeLa cell sublines.

In Vitro Cell. Dev. Biol. Anim. 28:553-556(1992)

PubMed=8380785; DOI=10.1006/gyno.1993.1016

Iwasaka T., Oh-uchida M., Matsuo N., Yokoyama M., Fukuda K., Hara K., Fukuyama K., Hori K., Sugimori H.

Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines.

Gynecol. Oncol. 48:104-109(1993)

PubMed=9892199

Macville M.V.E., Schrock E., Padilla-Nash H.M., Keck C., Ghadimi B.M., Zimonjic D.B., Popescu N.C., Ried T.

Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping.

Cancer Res. 59:141-150(1999)

PubMed=10423141; DOI=10.1099/0022-1317-80-7-1725

Meissner J.D.

Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines.

J. Gen. Virol. 80:1725-1733(1999)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=11668190; DOI=10.1177/002215540104901105

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

Immunocytochemical analysis of cell lines derived from solid tumors.

J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=12001993; DOI=10.1038/nrc775

Masters J.R.W.

HeLa cells 50 years on: the good, the bad and the ugly.

Nat. Rev. Cancer 2:315-319(2002)

PubMed=12793746; DOI=10.1269/jrr.43.s133

Ohnishi T., Ohnishi K., Takahashi A., Taniguchi Y., Sato M., Nakano T., Nagaoka S.

Detection of DNA damage induced by space radiation in Mir and space shuttle.

J. Radiat. Res. 43 Suppl. 1:S133-S136(2002)

PubMed=12661003; DOI=10.1002/gcc.10196

Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., Scherneck S.

Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.

Genes Chromosomes Cancer 37:29-35(2003)

PubMed=15302935; DOI=10.1073/pnas.0404720101; PMCID=PMC514446

Beausoleil S.A., Jedrychowski M.P., Schwartz D., Elias J.E., Villen J., Li J.-X., Cohn M.A., Cantley L.C., Gygi S.P.

Large-scale characterization of HeLa cell nuclear phosphoproteins.

Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004)

PubMed=15531914; DOI=10.1038/sj.onc.1208235

Baldus S.E., Schwarz E., Lohrey C., Zapatka M., Landsberg S., Hahn S.A., Schmidt D., Dienes H.-P., Schmiegel W.H., Schwarte-Waldhoff I.

Smad4 deficiency in cervical carcinoma cells.

Oncogene 24:810-819(2005)

PubMed=15901131; DOI=10.1016/j.prp.2005.01.002

Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.

Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.

Pathol. Res. Pract. 201:109-115(2005)

PubMed=17311676; DOI=10.1186/1471-2164-8-53; PMCID=PMC1805756

Kloth J.N., Oosting J., van Wezel T., Szuhai K., Knijnenburg J., Gorter A., Kenter G.G., Fleuren G.J., Jordanova E.S.

Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer.

BMC Genomics 8:53.1-53.13(2007)

PubMed=19450234; DOI=10.2144/000113089; PMCID=PMC2696096

Rahbari R., Sheahan T., Modes V., Collier P., Macfarlane C.M., Badge R.M.

A novel L1 retrotransposon marker for HeLa cell line identification.

BioTechniques 46:277-284(2009)

PubMed=19722756; DOI=10.5858/133.9.1463

Lucey B.P., Nelson-Rees W.A., Hutchins G.M.

Henrietta Lacks, HeLa cells, and cell culture contamination.

Arch. Pathol. Lab. Med. 133:1463-1467(2009)

CLPUB00377

Skloot R.L.

The immortal life of Henrietta Lacks.

(In book) ISBN 9781400052172; pp.1-400; Random House; New York; USA (2010)

CLPUB00468

Javitt G.H.

Why not take all of me? Reflections on the immortal life of Henrietta Lacks and the status of participants in research using human specimens.

Minn. J. Law Sci. Technol. 11:713-755(2010)

PubMed=19941903; DOI=10.1016/j.jviromet.2009.11.022

Karger A., Bettin B., Lenk M., Mettenleiter T.C.

Rapid characterisation of cell cultures by matrix-assisted laser desorption/ionisation mass spectrometric typing.

J. Virol. Methods 164:116-121(2010)

PubMed=21269460; DOI=10.1186/1752-0509-5-17; PMCID=PMC3039570

Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.

Initial characterization of the human central proteome.

BMC Syst. Biol. 5:17.1-17.13(2011)

PubMed=22068331; DOI=10.1038/msb.2011.81; PMCID=PMC3261714

Nagaraj N., Wisniewski J.R., Geiger T., Cox J., Kircher M., Kelso J., Paabo S., Mann M.

Deep proteome and transcriptome mapping of a human cancer cell line.

Mol. Syst. Biol. 7:548-548(2011)

PubMed=21937730; DOI=10.1074/mcp.M111.011429; PMCID=PMC3316722

Boisvert F.-M., Ahmad Y., Gierlinski M., Charriere F., Lamont D., Scott M., Barton G., Lamond A.I.

A quantitative spatial proteomics analysis of proteome turnover in human cells.

Mol. Cell. Proteomics 11:M111.011429-M111.011429(2012)

PubMed=22278370; DOI=10.1074/mcp.M111.014050; PMCID=PMC3316730

Geiger T., Wehner A., Schaab C., Cox J., Mann M.

Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.

Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=22412903; DOI=10.1371/journal.pone.0032667; PMCID=PMC3296745

Vazquez-Mena O., Medina-Martinez I., Juarez-Torres E., Barron V., Espinosa A., Villegas-Sepulveda N., Gomez-Laguna L., Nieto-Martinez K., Orozco L., Roman-Bassaure E., Munoz Cortez S., Borges Ibanez M., Venegas-Vega C.A., Guardado-Estrada M., Rangel-Lopez A., Kofman S., Berumen J.

Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines.

PLoS ONE 7:E32667-E32667(2012)

CLPUB00507

Pultarova T.

HeLa cells: immortal space travellers.

Space Saf. Mag. 7:10-12(2013)

PubMed=23205564; DOI=10.1021/pr300859k

Malerod H., Graham R.L.J., Sweredoski M.J., Hess S.

Comprehensive profiling of N-linked glycosylation sites in HeLa cells using hydrazide enrichment.

J. Proteome Res. 12:248-259(2013)

PubMed=23336012; DOI=10.1371/journal.pone.0054672; PMCID=PMC3545996

Horvat T., Dezeljin M., Redzic I., Barisic D., Herak Bosnar M., Lauc G., Zoldos V.

Reversibility of membrane N-glycome of HeLa cells upon treatment with epigenetic inhibitors.

PLoS ONE 8:E54672-E54672(2013)

PubMed=23925224; DOI=10.1038/500141a; PMCID=PMC5101952

Hudson K.L., Collins F.S.

Biospecimen policy: family matters.

Nature 500:141-142(2013)

PubMed=23925245; DOI=10.1038/nature12064; PMCID=PMC3740412

Adey A.C., Burton J.N., Kitzman J.O., Hiatt J.B., Lewis A.P., Martin B.K., Qiu R.-L., Lee C., Shendure J.

The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line.

Nature 500:207-211(2013)

PubMed=24134916; DOI=10.1186/1755-8166-6-44; PMCID=PMC3879223

McCormack A., Fan J.-L., Duesberg M., Bloomfield M., Fiala C., Duesberg P.H.

Individual karyotypes at the origins of cervical carcinomas.

Mol. Cytogenet. 6:44.1-44.23(2013)

PubMed=24618588; DOI=10.1371/journal.pone.0091433; PMCID=PMC3950186

Chernobrovkin A.L., Zubarev R.A.

Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.

PLoS ONE 9:E91433-E91433(2014)

PubMed=24696503; DOI=10.1074/mcp.M113.035170; PMCID=PMC4047476

Guo X.-F., Trudgian D.C., Lemoff A., Yadavalli S., Mirzaei H.

Confetti: a multiprotease map of the HeLa proteome for comprehensive proteomics.

Mol. Cell. Proteomics 13:1573-1584(2014)

PubMed=24908793

Gilgenkrantz S.

Sixty years of HeLa cell cultures.

Hist. Sci. Med. 48:139-144(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)

CLPUB00376

Verspaget C.J.

Unruly bodies: monstrous readings of biotechnology.

Thesis PhD (2015); Curtin University; Perth; Australia

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25807930; DOI=10.1002/anie.201500342; PMCID=PMC4471546

Broncel M., Serwa R.A., Ciepla P., Krause E., Dallman M.J., Magee A.I., Tate E.W.

Multifunctional reagents for quantitative proteome-wide analysis of protein modification in human cells and dynamic profiling of protein lipidation during vertebrate development.

Angew. Chem. Int. Ed. Engl. 54:5948-5951(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314; PMCID=PMC4404347

Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.

A mass spectrometric-derived cell surface protein atlas.

PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26554430; DOI=10.1021/acs.analchem.5b03639

Dimayacyac-Esleta B.R.T., Tsai C.-F., Kitata R.B., Lin P.-Y., Choong W.-K., Lin T.-D., Wang Y.-T., Weng S.-H., Yang P.-C., Arco S.D., Sung T.-Y., Chen Y.-J.

Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling.

Anal. Chem. 87:12016-12023(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28078501; DOI=10.1007/s11626-016-0128-8

Ambrose C.T.

The Tissue Culture Laboratory of Dr. George Otto Gey 60 yrs ago as recalled by a former student.

In Vitro Cell. Dev. Biol. Anim. 53:467-473(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=28261610; DOI=10.1155/2017/4180703; PMCID=PMC5316418

Kontostathi G., Zoidakis J., Makridakis M., Lygirou V., Mermelekas G., Papadopoulos T., Vougas K., Vlamis-Gardikas A., Drakakis P., Loutradis D., Vlahou A., Anagnou N.P., Pappa K.I.

Cervical cancer cell line secretome highlights the roles of transforming growth factor-beta-induced protein ig-h3, peroxiredoxin-2, and NRF2 on cervical carcinogenesis.

BioMed Res. Int. 2017:4180703.1-4180703.15(2017)

PubMed=28601559; DOI=10.1016/j.cels.2017.05.009; PMCID=PMC5493283

Bekker-Jensen D.B., Kelstrup C.D., Batth T.S., Larsen S.C., Haldrup C., Bramsen J.B., Sorensen K.D., Hoyer S., Orntoft T.F., Lindbjerg Andersen C., Nielsen M.L., Olsen J.V.

An optimized shotgun strategy for the rapid generation of comprehensive human proteomes.

Cell Syst. 4:587-599.e4(2017)

PubMed=29156801; DOI=10.18632/oncotarget.21174; PMCID=PMC5689691

Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y., Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J., Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.

Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.

Oncotarget 8:86369-86383(2017)

PubMed=30175587; DOI=10.1021/acs.jproteome.8b00392

Robin T., Bairoch A., Muller M., Lisacek F., Lane L.

Large-scale reanalysis of publicly available HeLa cell proteomics data in the context of the Human Proteome Project.

J. Proteome Res. 17:4160-4170(2018)

PubMed=30778230; DOI=10.1038/s41587-019-0037-y

Liu Y.-S., Mi Y., Mueller T., Kreibich S., Williams E.G., Van Drogen A., Borel C., Frank M., Germain P.-L., Bludau I., Mehnert M., Seifert M., Emmenlauer M., Sorg I., Bezrukov F., Sloan-Bena F., Zhou H., Dehio C., Testa G., Saez-Rodriguez J., Antonarakis S.E., Hardt W.-D., Aebersold R.

Multi-omic measurements of heterogeneity in HeLa cells across laboratories.

Nat. Biotechnol. 37:314-322(2019)

PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132; PMCID=PMC6548687

Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P., Mitra R., Nonn L., Kimbro K.S., Kittles R.A.

Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines.

Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31433507; DOI=10.15252/embj.2018100847; PMCID=PMC6826212

Hardman G., Perkins S., Brownridge P.J., Clarke C.J., Byrne D.P., Campbell A.E., Kalyuzhnyy A., Myall A., Eyers P.A., Jones A.R., Eyers C.E.

Strong anion exchange-mediated phosphoproteomics reveals extensive human non-canonical phosphorylation.

EMBO J. 38:e100847.1-e100847.22(2019)

PubMed=31790455; DOI=10.1371/journal.pone.0225466; PMCID=PMC6886862

Hu W.-E., Zhang X., Guo Q.-F., Yang J.-W., Yang Y., Wei S.-C., Su X.-D.

HeLa-CCL2 cell heterogeneity studied by single-cell DNA and RNA sequencing.

PLoS ONE 14:E0225466-E0225466(2019)

PubMed=33389257; DOI=10.1007/s10096-020-04106-0; PMCID=PMC7778494

Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.

Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile.

Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021)"